Related Experiment Video
Updated: Feb 19, 2026

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles
Published on: November 17, 2018
Personalized neoantigen vaccines: A new approach to cancer immunotherapy
Amanda R Aldous1, Jesse Z Dong1
1Neon Therapeutics, Cambridge, MA 02139, USA.
Abstract:
Neoantigens arise from somatic mutations that differ from wild-type antigens and are specific to each individual patient, which provide tumor specific targets for developing personalized cancer vaccines. Decades of work has increasingly shown the potential of targeting neoantigens to generate effective clinical responses. Current clinical trials using neoantigen targeting cancer vaccines, including in combination with checkpoint blockade monoclonal antibodies, have demonstrated potent T-cell responses against those neoantigens accompanied by antitumor effects in patients. Personalized neoantigen vaccines represent a potential new class of cancer immunotherapy.
Insights
Personalized cancer vaccines target neoantigens, which are unique to each patient. Clinical trials show these vaccines, often with checkpoint inhibitors, generate strong T-cell responses and antitumor effects.
Area of Science:
- Oncology
- Immunology
- Vaccinology
Background:
- Neoantigens are derived from somatic mutations, distinguishing them from wild-type antigens.
- Neoantigens are patient-specific, offering targeted therapeutic opportunities.
- Research over decades highlights the potential of neoantigen targeting for effective cancer treatment.
Purpose of the Study:
- To explore the potential of personalized neoantigen vaccines in cancer immunotherapy.
- To evaluate the clinical efficacy of neoantigen-targeting vaccines.
Main Methods:
- Utilizing neoantigens as specific targets for vaccine development.
- Conducting clinical trials with neoantigen vaccines, including combinations with checkpoint blockade antibodies.
Main Results:
- Demonstrated potent T-cell responses against targeted neoantigens in patients.
- Observed significant antitumor effects in clinical trials.
- Validated the immunogenicity and therapeutic potential of personalized neoantigen vaccines.
Conclusions:
- Personalized neoantigen vaccines show promise as a novel class of cancer immunotherapy.
- Neoantigen-based strategies, especially in combination therapies, are effective in eliciting anti-tumor immunity.
Related Concept Videos
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Tumor Immunotherapy
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

